Tirzepatide Protocol for Med Spas: What Compliance Requires in 2026

Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for weight management — is one of the most in-demand treatments at aesthetic and wellness med spas. With clinical trials showing 20%+ body weight reduction, patient demand has been extraordinary.

But the regulatory landscape shifted significantly in 2025–2026. The FDA declared both semaglutide and Tirzepatide shortages resolved, triggering restrictions on compounded versions. Med spas that haven't updated their Tirzepatide protocols are now operating with serious compliance gaps — gaps that can lead to DEA scrutiny, board action, and malpractice exposure.

This guide covers exactly what a compliant Tirzepatide protocol must include in 2026.

What Is Tirzepatide and Why Do Med Spas Offer It?

Tirzepatide is a dual GIP/GLP-1 receptor agonist — meaning it activates two different hormone pathways that regulate blood sugar and appetite. This dual mechanism produces greater weight loss than GLP-1-only medications like semaglutide.

FDA-approved indications:

• Mounjaro (Tirzepatide): Type 2 diabetes management (FDA approved May 2022)
• Zepbound (Tirzepatide): Chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related condition (FDA approved November 2023)

Med spas typically prescribe Zepbound (or off-label Mounjaro) for weight management in eligible patients. This is legal when done properly — but "properly" requires a complete written protocol.

The 2026 Compounding Rule Change: What It Means for Your Practice

During the FDA shortage of Tirzepatide (2023–2024), 503A and 503B compounding pharmacies were permitted to produce compounded Tirzepatide because the shortage meant insufficient branded supply. This created a grey market where many med spas obtained inexpensive compounded Tirzepatide.

The FDA declared the Tirzepatide shortage resolved in late 2024 / early 2025. Under federal law, 503A compounding pharmacies can no longer compound Tirzepatide for general dispensing. Exceptions are narrow:

• Patient has a documented allergy to an inactive ingredient in the branded product that is not present in the compounded version
• Patient requires a dosage form or strength not commercially available (with documented clinical justification)
• 503B outsourcing facilities have different (and temporarily extended) timelines

Bottom line for 2026: If your practice is still using compounded Tirzepatide from a 503A pharmacy without documented patient-specific clinical justification, you are in violation of federal compounding law. Update your SOP immediately.

Core Elements of a Compliant Tirzepatide Protocol

1. Patient Selection and Eligibility Criteria

Your SOP must clearly define who qualifies for Tirzepatide therapy. For Zepbound (FDA-approved indication), eligibility includes:

• BMI ≥ 30 kg/m² (obesity), OR
• BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity: hypertension, type 2 diabetes, hyperlipidemia, obstructive sleep apnea, or cardiovascular disease
• Commitment to lifestyle modification (diet, exercise) as part of the program
• No contraindications (see below)

2. Good Faith Exam (GFE) Requirements

A Good Faith Exam is mandatory before prescribing any prescription medication. For Tirzepatide, the GFE must document:

• Current height, weight, and BMI
• Blood pressure and heart rate
• Complete medication list (drug interactions)
• Relevant medical history (thyroid, pancreatic, GI, cardiac)
• Personal and family history of thyroid cancer or MEN 2
• Prior weight loss treatments and outcomes
• Lab results (baseline metabolic panel, HbA1c, lipids if available)
• Clinical rationale for prescribing Tirzepatide specifically
• Discussion of risks, benefits, and alternatives

The prescriber performing the GFE must be licensed to prescribe in your state and must have a legitimate patient-provider relationship. Telehealth GFEs are permissible in most states when conducted via synchronous video visit (not just an online questionnaire).

3. Contraindications Screening

These must be screened and documented at the GFE:

• Absolute contraindications:
  • Personal or family history of Medullary Thyroid Carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known hypersensitivity to Tirzepatide or any excipient
• Relative contraindications (use with caution and document decision):
  • History of pancreatitis
  • Severe GI disease (gastroparesis, inflammatory bowel disease)
  • Severe renal impairment
  • Pregnancy or plans for pregnancy (discontinue at least 2 months before conception)
  • Active gallbladder disease

4. Dosing Protocol and Titration Schedule

Your Tirzepatide SOP must specify the approved dosing schedule:

• Starting dose: 2.5 mg subcutaneous injection, once weekly for 4 weeks
• Dose escalation: Increase by 2.5 mg every 4 weeks as tolerated
• Maintenance doses: 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg weekly
• Maximum approved dose: 15 mg/week
• Escalation hold criteria: Moderate-to-severe GI symptoms, unable to tolerate current dose — hold at current dose for additional 4 weeks before escalating

The dose escalation decision should be made or approved by the supervising physician and documented in the patient chart. Nurse practitioners and PAs may manage titration within standing orders established by the medical director.

5. Injection Technique and Administration SOP

Patient self-injection training should be documented and include:

• Subcutaneous injection technique (abdomen, thigh, or upper arm)
• Needle disposal (sharps container) instructions
• Storage requirements (refrigerator 36–46°F; may be stored at room temperature up to 86°F for up to 21 days)
• Missed dose protocol (inject as soon as remembered if within 4 days; skip if more than 4 days late)
• What to do if a dose is dropped or contaminated

6. Monitoring Protocol

Ongoing monitoring must be documented in your SOP:

• Every visit: Weight, BMI, blood pressure, heart rate, side effect assessment
• Monthly during titration: Clinical check-in (in-person or telehealth) to assess tolerance and adjust dose
• Every 3 months: Metabolic panel, HbA1c (especially in patients with pre-diabetes or diabetes)
• Every 6 months: Lipid panel, review of weight loss progress and continued clinical benefit
• Ongoing: Symptom screening for pancreatitis (abdominal pain, nausea, vomiting), gallbladder disease (right upper quadrant pain), and thyroid nodules

7. Discontinuation Criteria

Your SOP should define when Tirzepatide should be stopped:

• Inadequate response after 16 weeks at a therapeutic dose (less than 5% weight loss)
• Intolerable side effects that do not resolve with dose reduction
• Diagnosis of a contraindication (MTC diagnosis, MEN 2 diagnosis, confirmed pancreatitis)
• Patient pregnancy or confirmed pregnancy
• Patient request
• Unacceptable deviation from recommended lifestyle modifications

8. Documentation and Charting Requirements

Every patient interaction must be documented in the medical record:

• GFE findings and prescribing decision
• Prescription details (drug, dose, quantity, instructions)
• Patient education provided and acknowledgment
• Weight, vitals, and symptom assessment at each visit
• Dose changes and rationale
• Any adverse events and how they were managed
• Annual protocol review by medical director

What Puts Your Tirzepatide Practice at Risk

Common compliance failures seen in med spa Tirzepatide programs:

• No documented GFE: Prescribing based on an online questionnaire without a synchronous provider evaluation
• Continuing compounded Tirzepatide: Using 503A compounded product without documented patient-specific justification after the shortage ended
• No monitoring protocol: Prescribing refills without any follow-up contact or chart documentation
• No medical director oversight: NP or PA prescribing without standing orders or physician supervision as required by state law
• Inadequate informed consent: Patients not informed of the thyroid cancer warning label, pancreatitis risk, or need to discontinue before pregnancy
• Off-label use without documentation: Prescribing Mounjaro (diabetes indication) for weight loss without documenting the off-label rationale

Key Takeaways

1. Use branded Tirzepatide (Zepbound) unless there is documented patient-specific justification for compounded
2. Every patient needs a Good Faith Exam with complete documentation before the first prescription
3. Your SOP must specify dosing, titration, monitoring, and discontinuation criteria
4. Medical director supervision and standing orders are required in all states
5. Chart every interaction — weight, vitals, symptom assessment, dose decisions
6. Screen and document all contraindications at baseline